JP2022521824A5 - - Google Patents

Info

Publication number
JP2022521824A5
JP2022521824A5 JP2021557651A JP2021557651A JP2022521824A5 JP 2022521824 A5 JP2022521824 A5 JP 2022521824A5 JP 2021557651 A JP2021557651 A JP 2021557651A JP 2021557651 A JP2021557651 A JP 2021557651A JP 2022521824 A5 JP2022521824 A5 JP 2022521824A5
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
inhibitor
pharmaceutical composition
combination according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021557651A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521824A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025539 external-priority patent/WO2020198710A1/en
Publication of JP2022521824A publication Critical patent/JP2022521824A/ja
Publication of JP2022521824A5 publication Critical patent/JP2022521824A5/ja
Ceased legal-status Critical Current

Links

JP2021557651A 2019-03-28 2020-03-27 アンドロゲン受容体の阻害剤を含む薬学的組成物及びその組み合わせならびにその使用 Ceased JP2022521824A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962825450P 2019-03-28 2019-03-28
US62/825,450 2019-03-28
US201962842980P 2019-05-03 2019-05-03
US62/842,980 2019-05-03
US201962857519P 2019-06-05 2019-06-05
US62/857,519 2019-06-05
PCT/US2020/025539 WO2020198710A1 (en) 2019-03-28 2020-03-27 Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof

Publications (2)

Publication Number Publication Date
JP2022521824A JP2022521824A (ja) 2022-04-12
JP2022521824A5 true JP2022521824A5 (enExample) 2023-04-04

Family

ID=72610726

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557651A Ceased JP2022521824A (ja) 2019-03-28 2020-03-27 アンドロゲン受容体の阻害剤を含む薬学的組成物及びその組み合わせならびにその使用

Country Status (10)

Country Link
US (1) US20220202780A1 (enExample)
EP (1) EP3947353A4 (enExample)
JP (1) JP2022521824A (enExample)
KR (1) KR20210144827A (enExample)
CN (1) CN114502539A (enExample)
AU (1) AU2020248105A1 (enExample)
CA (1) CA3134545A1 (enExample)
IL (1) IL286726A (enExample)
MX (1) MX2021011826A (enExample)
WO (1) WO2020198710A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10471023B2 (en) 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
WO2019226991A1 (en) 2018-05-25 2019-11-28 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
US12637418B2 (en) 2019-01-24 2026-05-26 Takeda Pharmaceutical Company Limited Heterocyclic compounds as antagonist of NMDA
US12109179B2 (en) 2019-03-28 2024-10-08 Essa Pharma Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
TWI873185B (zh) 2019-09-16 2025-02-21 日商武田藥品工業股份有限公司 唑稠合之嗒-3(2h)-酮衍生物
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
AR121506A1 (es) 2020-03-03 2022-06-08 Pic Therapeutics Inc Inhibidores del eif4e y sus usos
EP4135675A4 (en) * 2020-04-17 2024-04-10 Essa Pharma, Inc. SOLID FORMS OF AN N-TERMINAL DOMAIN ANDROGEN RECEPTOR INHIBITOR AND USES THEREOF
WO2022060969A1 (en) * 2020-09-16 2022-03-24 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
WO2022169248A1 (ko) * 2021-02-02 2022-08-11 주식회사 엘지화학 단백질 키나아제 억제제로서의 신규한 화합물
CA3215182A1 (en) * 2021-04-16 2022-10-20 Han-Jie Zhou Pharmaceutical compositions comprising inhibitors of the androgen receptor and uses thereof
CN115340527B (zh) * 2021-05-13 2023-09-15 成都先导药物开发股份有限公司 一种bcl-xl抑制剂及其制备方法和用途
CN113603695B (zh) * 2021-08-05 2022-06-14 青岛恒宁生物科技有限公司 一种取代的嘧啶胺类化合物或其作为农药可接受的盐、组合物及其用途
IL310924A (en) 2021-08-25 2024-04-01 Pic Therapeutics Inc Eif4e inhibitors and uses thereof
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
AU2022340817A1 (en) * 2021-09-01 2024-03-14 Essa Pharma Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
US20240398797A1 (en) * 2021-09-01 2024-12-05 Janssen Pharmaceutica Nv Combination therapies for metastatic castration-resistant prostate cancer
WO2023151662A1 (zh) * 2022-02-10 2023-08-17 上海奕拓医药科技有限责任公司 雄激素受体活性调节剂及其应用
CN117065022A (zh) * 2022-05-17 2023-11-17 海创药业股份有限公司 一种治疗三阴乳腺癌的药物
WO2024006207A1 (en) * 2022-06-26 2024-01-04 Essa Pharma Inc. An n-terminal domain androgen receptor inhibitor and uses thereof
EP4626878A1 (en) 2022-12-02 2025-10-08 Neumora Therapeutics, Inc. Methods of treating neurological disorders
CN118255693A (zh) * 2024-03-28 2024-06-28 大连理工大学 联苯类化合物及其在制备治疗白血病、肺癌以及乳腺癌药物中的应用
CN121698845A (zh) * 2024-09-12 2026-03-20 青岛普泰科生物医药科技有限公司 一种四氢喹啉类ntd抑制剂及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0709771B1 (pt) * 2006-03-27 2022-01-25 The Regents Of The University Of California Composto e composição farmacêutica
ES2613098T3 (es) * 2011-08-19 2017-05-22 British Columbia Cancer Agency Branch Compuestos de éter de bisfenol fluorado y métodos para su uso
EP3733170A1 (en) * 2012-07-13 2020-11-04 Oncternal Therapeutics, Inc. A method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms)
FI3988541T3 (fi) * 2015-01-13 2024-09-17 British Columbia Cancer Agency Branch Heterosyklisiä yhdisteitä syövän kuvantamiseksi ja hoitamiseksi ja menetelmiä niiden käyttämiseksi
US10980806B2 (en) * 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
US20170298033A1 (en) * 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
WO2017223115A1 (en) * 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
AU2019362061B2 (en) * 2018-10-18 2024-09-26 Essa Pharma Inc Androgen receptor modulators and methods for their use

Similar Documents

Publication Publication Date Title
JP7094456B2 (ja) Cdk2阻害剤
JP6505013B2 (ja) スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
JP6172871B2 (ja) ヘテロアリール‐ケトン縮合アザデカリン糖質コルチコイドレセプター調節因子
JP5261575B2 (ja) 化学化合物
JP2022504949A5 (enExample)
KR102515507B1 (ko) 알파 v 인테그린 억제제로서의 피롤 아미드
TWI757722B (zh) 以雜環化合物作為激酶抑制劑的治療用途
TW201922722A (zh) 作為法尼醇x受體調節劑之橋聯雙環化合物
KR20220101137A (ko) Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도
KR20180088457A (ko) 벤조티오펜-기반 선택적 에스트로겐 수용체 하향조절제
JP2010018616A (ja) チロシンキナーゼおよびセリン/スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
CN104010639A (zh) 作为RORγt调节剂的酰胺类化合物及其应用
TWI759343B (zh) 新穎萘啶酮衍生物及其於心律不整之治療的用途
JPWO2000004014A1 (ja) 抗腫瘍活性を有するピリミジン誘導体
AU2005275279A1 (en) Arylidenes for the treatment of estrogen related receptor-alpha mediated diseases
KR20190117582A (ko) 벤조티오펜 에스트로겐 수용체 조정제
CN107814798B (zh) 3-取代丙烯酸类化合物及其制备方法和用途
JP6893516B2 (ja) 3−((ヘテロ−)アリール)−8−アミノ−2−オキソ−1,3−ジアザ−スピロ−[4.5]−デカン誘導体
AU2020371836A1 (en) Pyrrole amide compound and use thereof
JP2002088073A (ja) 抗アンドロゲン剤
CA2803055A1 (en) Heteroaryl compounds and compositions as protein kinase inhibitors
KR20200081435A (ko) 파르네소이드 x 수용체 조정제로서의 멀티시클릭 화합물
KR20240049811A (ko) Ddr1의 억제제로서 페닐- 및 피리도피라졸 유도체
WO2024047135A1 (en) Substituted heterocycles as ras inhibitors
JP6500092B2 (ja) T型カルシウムチャンネルブロッカーとしてのトリアゾール化合物